Cargando…

Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study

BACKGROUND: Alpha(1)-antitrypsin (AAT) deficiency is characterized by low blood levels of alpha(1)-proteinase inhibitor (alpha(1)-PI) and may lead to emphysema. Alpha(1)-PI protects pulmonary tissue from damage caused by the action of proteolytic enzymes. Augmentation therapy with Prolastin(® )(Alph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stocks, James M, Brantly, Mark L, Wang-Smith, Laurene, Campos, Michael A, Chapman, Kenneth R, Kueppers, Friedrich, Sandhaus, Robert A, Strange, Charlie, Turino, Gerard
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958874/ https://www.ncbi.nlm.nih.gov/pubmed/20920295 http://dx.doi.org/10.1186/1472-6904-10-13

Ejemplares similares

Therapy with Plasma Purified Alpha1-Antitrypsin (Prolastin(®)) Induces Time-Dependent Changes in Plasma Levels of MMP-9 and MPO
por: Koepke, Janine, et al.
Publicado: (2015)

Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine release
por: Nita, Izabela, et al.
Publicado: (2005)

Detection of alpha-1 antitrypsin deficiency: the past, present and future
por: Brantly, Mark, et al.
Publicado: (2020)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
por: McGee, Dawn, et al.
Publicado: (2010)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life
por: Beiko, Tatsiana, et al.
Publicado: (2019)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Clinical presentations of four patients with rare Alpha 1 Antitrypsin variants identified in a single US center
por: Kueppers, Friedrich
Publicado: (2021)

Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency.
por: Sharp, Richard R, et al.
Publicado: (2003)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
por: Al Ashry, Haitham S., et al.
Publicado: (2017)

An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency
por: Attaway, Amy, et al.
Publicado: (2019)

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency
por: Mayer, Annyce S, et al.
Publicado: (2006)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function
por: Kokturk, Nurdan, et al.
Publicado: (2023)

Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
por: Herth, Felix J F, et al.
Publicado: (2021)

Alpha 1 Antitrypsin-Deficient Macrophages Have Impaired Efferocytosis of Apoptotic Neutrophils
por: Lee, Jungnam, et al.
Publicado: (2020)

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank
por: Tonelli, Adriano R, et al.
Publicado: (2009)

Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency
por: Chapman, Kenneth R.
Publicado: (2020)

Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency
por: Kueppers, Friedrich, et al.
Publicado: (2019)

Development of a risk score to increase detection of severe alpha-1 antitrypsin deficiency
por: Riley, E. Leonard, et al.
Publicado: (2023)

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease
por: Serban, K.A., et al.
Publicado: (2022)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Quantitative measurement of the histological features of alpha-1 antitrypsin deficiency-associated liver disease in biopsy specimens
por: Marek, George, et al.
Publicado: (2021)

Alpha-1 antitrypsin deficient individuals have circulating extracellular vesicles with profibrogenic cargo
por: Khodayari, Nazli, et al.
Publicado: (2020)

The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease
por: Khodayari, Nazli, et al.
Publicado: (2021)

Relationship Between α(1)-Antitrypsin Deficiency and Ascending Aortic Distention
por: Dako, Farouk, et al.
Publicado: (2021)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Intrahepatic heteropolymerization of M and Z alpha-1-antitrypsin
por: Laffranchi, Mattia, et al.
Publicado: (2020)

The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency
por: Campos, Michael A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tjb1ipvdi218m57nrvi5fet1mo